Ingenium Therapeutics Novel NK Cell Therapy Receives ODD

Ingenium Therapeutics Novel NK Cell Therapy Receives ODD

By, Admin 1 May 2024

Overview

Breakthrough Technology Empowers NK Cell Therapy for Acute Myeloid Leukemia Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

Ingenium's Technology

  • Ingenium's proprietary technology enables the company to differentiate and proliferate natural killer (NK) cells with superior anti-cancer efficacy. 
  • By targeting CD3-negative immune cells, the company can acquire a large number of highly pure NK cells in a relatively short timeframe. 
  • This mass-produced, allogeneic NK cell therapy derived from healthy donors demonstrates potent anti-cancer effects with high purity and activity.

Words from CEO: Ingenium Therapeutics

  • "We are delighted to have received Orphan Drug Designation for IGNK001 from the FDA, recognizing the potential of our innovative NK cell therapy technology," said Ko Jin-ok, CEO of Ingenium Therapeutics.
  • "Gengluecel has already received approval from the Korean Ministry of Food and Drug Safety for phase 2 clinical trials, and we are preparing to initiate clinical trials in the U.S. targeting 80 subjects with the goal of completing the studies by December 2027."

ODD for Ingenium

The Orphan Drug Designation provides Ingenium with various development incentives, including tax credits for qualified clinical trials, exemption from FDA application fees, and a potential seven-year period of market exclusivity upon regulatory approval.

About Ingenium Therapeutics

  • Ingenium Therapeutics is a pioneering biopharmaceutical company dedicated to developing next-generation NK cell therapies. 
  • The company's innovative technology platform enables the production of highly potent, allogeneic NK cells with enhanced anti-cancer capabilities. 
  • Ingenium is committed to advancing its lead candidate, IGNK001 (Gengluecel), through clinical development and regulatory approval to provide new treatment options for patients with acute myeloid leukemia and other hematological malignancies. For more information

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!